Multi-Biomarker Pattern for Tumor Identification and Prognosis

被引:25
作者
Rodriguez-Enriquez, Sara [1 ,2 ]
Cecilia Pacheco-Velazquez, Silvia [1 ]
Carlos Gallardo-Perez, Juan [1 ]
Marin-Hernandez, Alvaro [1 ]
Luis Aguilar-Ponce, Jose [2 ]
Ruiz-Garcia, Erika [2 ]
Maria RuizGodoy-Rivera, Luz [2 ,3 ]
Meneses-Garcia, Abelardo [2 ,3 ]
Moreno-Sanchez, Rafael [1 ]
机构
[1] Inst Nacl Cardiol, Dept Biochem, Tlalpan, Mexico
[2] Inst Nacl Cancerol, Lab Translat Med, Tlalpan, Mexico
[3] Inst Nacl Cancerol, Dept Tumor Bank, Tlalpan, Mexico
关键词
METABOLIC BIOMARKERS; BIOMARKER PATTERNS; HIF-1; alpha; GLYCOLYTIC GENES; CELL LUNG-CANCER; ENDOTHELIAL GROWTH-FACTOR; LYSYL OXIDASE EXPRESSION; METASTATIC BREAST-CANCER; INDUCIBLE FACTOR 1-ALPHA; SURROGATE END-POINTS; COLORECTAL-CANCER; ESTROGEN-RECEPTOR; OVARIAN-CANCER; MICROSATELLITE ALTERATIONS;
D O I
10.1002/jcb.23224
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In last decades, the basic, clinical, and translational research efforts have been directed to the identification of standard biomarkers associated with the degree of malignancy. There is an increasingly public health concern for earlier detection of cancer development at stages in which successful treatments can be achieved. To meet this urgent clinical demand, early stage cancer biomarkers supported by reliable and robust experimental data that can be readily applicable in the clinical practice, are required. In the current standard protocols, when one or two of the canonical proliferating index biomarkers are analyzed, contradictory results are frequently reached leading to incorrect cancer diagnostic and unsuccessful therapies. Therefore, the identification of other cellular characteristics or signatures present in the tumor cells either alone or in combination with the well-established proliferation markers emerge as an alternative strategy in the improvement of cancer diagnosis and treatment. Because it is well known that several pathways and processes are altered in tumor cells, the concept of "single marker" in cancer results incorrect. Therefore, this review aims to analyze and discuss the proposal that the molecular profile of different genes or proteins in different altered tumor pathways must be established to provide a better global clinical pattern for cancer detection and prognosis. J. Cell. Biochem. 112: 2703-2715, 2011. (C) 2011 Wiley-Liss, Inc.
引用
收藏
页码:2703 / 2715
页数:13
相关论文
共 144 条
[61]  
Kacser H, 1973, Symp Soc Exp Biol, V27, P65
[62]   Ovarian cancer: the duplicity of CA125 measurement [J].
Karam, Amer K. ;
Karlan, Beth Y. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (06) :335-339
[63]   K-ras mutations and benefit from cetuximab in advanced colorectal cancer [J].
Karapetis, Christos S. ;
Khambata-Ford, Shirin ;
Jonker, Derek J. ;
O'Callaghan, Chris J. ;
Tu, Dongsheng ;
Tebbutt, Niall C. ;
Simes, R. John ;
Chalchal, Haji ;
Shapiro, Jeremy D. ;
Robitaille, Sonia ;
Price, Timothy J. ;
Shepherd, Lois ;
Au, Heather-Jane ;
Langer, Christiane ;
Moore, Malcolm J. ;
Zalcberg, John R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (17) :1757-1765
[64]  
Kemik O, 2010, BRATISL MED J, V111, P485
[65]  
Kim HT, 1998, AM J MED GENET, V80, P391, DOI 10.1002/(SICI)1096-8628(19981204)80:4<391::AID-AJMG16>3.0.CO
[66]  
2-H
[67]  
Kim YS, 2001, CLIN CANCER RES, V7, P4008
[68]   Hypoxia and oxidative stress in breast cancer - Hypoxia and tumourigenesis [J].
Knowles, HJ ;
Harris, AL .
BREAST CANCER RESEARCH, 2001, 3 (05) :318-322
[69]   Relationships between hypoxia markers and the leptin system, estrogen receptors in human primary and metastatic breast cancer: effects of preoperative chemotherapy [J].
Koda, Mariusz ;
Kanczuga-Koda, Luiza ;
Sulkowska, Mariola ;
Surmacz, Eva ;
Sulkowski, Stanislaw .
BMC CANCER, 2010, 10
[70]   Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis [J].
Koukourakis, MI ;
Giatromanolaki, A ;
Sivridis, E ;
Bougioukas, G ;
Didilis, V ;
Gatter, KC ;
Harris, AL .
BRITISH JOURNAL OF CANCER, 2003, 89 (05) :877-885